

Table S2. Drug survival for all biological therapies according to therapeutic targets.-DUDA

Drugs by therapeutic target	Drug Survival- All treatments							
	N	Events	MST (mo)	IC95%	Log-Rank p-value	Univariate Cox Model		
						HR	IC95%	p-value
ANTI-TNF	247	193	24	18-31	0.07	1		
ANTI-IL12/23	132	87	36	25-44		0.75	0.58-0.97	0.0316

MST: median survival time (months)

HR: hazard ratio

IC95%: 95% confidence interval

NA: not achieved

Anti-TNF: Tumour Necrosis Factor inhibitor (Adalimumab, Certolizumab pegol, Etanercept and Infliximab)

Anti-IL12/23: interleukin 12 and interleukin 23 inhibitor (Ustekinumab)

Statistically significant values are coloured in grey, tendency to significance in bold.

